Shanghai Fosun Pharmaceutical (SHA:600196) secured approval from China's medical products administrator to conduct clinical trials for its HLX43 injection.
The drug will be used to treat advanced or metastatic solid tumors, according to a Wednesday filing with the Shanghai bourse.
Shares of the pharmaceutical company were down 1% in recent trade.